Ann: COVID ARDS Trial Topline 60-Day Results, page-1536

The American media and markets particularly seem to be ignoring the 2-3,000 deaths they still have a week from C-19 and the pressing delta variant dangers. Some figures from the English health authority study:

Fully vaccinated, efficacy in the Pfizer vaccine is 94% for the Alpha variant and 88% against the Delta variant. Fully vaccinated with the AstraZeneca vaccine, efficacy is 74% for the Alpha variant and 67% for the Delta variant. The delta variant is around 60% transmissable than the Aplha variant. It doubles the likelihood of hospitalization in non-vaccinated cases. Effectiveness against hospital admission was 92% in AstraZenica and 96% in the case of Pfizer.

It all sounds very positve, but the problem with all these percentage comparisons is they are against unvaccinated data. We need base figures. A more telling figure is that of 806 people admitted to hospital with the delta variant of the virus shown in the study, 84 of the 806 were fully vaccinated and 195 had one dose. It very difficult to get accurate infection rates, hospitalization rates, etc. But the number of delta hospitalizations doubled in weeks and it seems pretty clear that even in well vaccinated countries there are still going to be plenty of hospitalizations with COVID-19 alas, particularly in evolving strains like the Delta variant.

Its very clear there will still be a marginal, but not insignificant number of people critically contracting COVID-19 cases. Whilst the mainstream media may think full vaccination is simply the answer overseas, those of us looking at the data can see there is clearly still a very pressing need for treatments like MSB's Remestemcel-L in a pandemic that will persist in killing people even if they achieved 100% vaccination.